Status:

RECRUITING

An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC

Lead Sponsor:

Lu Shun

Conditions:

Non-small Cell Lung Cancer Metastatic

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

Brief Summary

This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of Oba01 for injection in patients with DR5 positive LA/mNSCLC.

Eligibility Criteria

Inclusion

  • Voluntary agreement to provide written informed consent.
  • Man or woman ≥ 18 years and ≤75 years of age at the time of enrollment.
  • Histologically and/or cytologically-confirmed locally advanced or metastatic NSCLC.
  • Measurable lesion according to RECIST 1.1.
  • Progression after systemic treatment for advanced NSCLC.
  • Available archived paraffin-embedded or fresh tumor tissue from the primary tumor or metastasis for submission to the central laboratory.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Measurable and/or non-measurable disease as per RECIST 1.1 criteria.
  • Adequate organ function as assessed by laboratory tests.
  • Male or female subjects of child-producing potential must agree to use avoidance of pregnancy measures during the study and for 6 months after the last day of treatment.

Exclusion

  • Patient has received previous treatment with DR5 targeted regimen or antibody-MMAE conjugate.
  • Brain metastases unless asymptomatic, stable and not requiring steroids for at least 7 days prior to start of study treatment.
  • Subject with positive HCV-Ab, Anti-HIV or positive HBS-Ag with copies of HBV DNA \> ULN.
  • Pregnancy, lactation, or breastfeeding.

Key Trial Info

Start Date :

December 13 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2026

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT06083870

Start Date

December 13 2023

End Date

July 1 2026

Last Update

December 20 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University

Shanghai, China, 200030